235 related articles for article (PubMed ID: 29259100)
1. mGluR5 antagonism increases autophagy and prevents disease progression in the
Abd-Elrahman KS; Hamilton A; Hutchinson SR; Liu F; Russell RC; Ferguson SSG
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259100
[TBL] [Abstract][Full Text] [Related]
2. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
Abd-Elrahman KS; Ferguson SSG
Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
[TBL] [Abstract][Full Text] [Related]
3. Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models.
Abd-Elrahman KS; Hamilton A; Vasefi M; Ferguson SSG
Mol Brain; 2018 Apr; 11(1):19. PubMed ID: 29631635
[TBL] [Abstract][Full Text] [Related]
4. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice.
Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
Front Mol Neurosci; 2022; 15():801757. PubMed ID: 35185467
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
[TBL] [Abstract][Full Text] [Related]
7. mGluR5 regulates REST/NRSF signaling through N-cadherin/β-catenin complex in Huntington's disease.
de Souza JM; Abd-Elrahman KS; Ribeiro FM; Ferguson SSG
Mol Brain; 2020 Aug; 13(1):118. PubMed ID: 32859226
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
[TBL] [Abstract][Full Text] [Related]
9. ULK1-mediated phosphorylation of ATG14 promotes autophagy and is impaired in Huntington's disease models.
Wold MS; Lim J; Lachance V; Deng Z; Yue Z
Mol Neurodegener; 2016 Dec; 11(1):76. PubMed ID: 27938392
[TBL] [Abstract][Full Text] [Related]
10. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
[TBL] [Abstract][Full Text] [Related]
11. Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease.
Ribeiro FM; Hamilton A; Doria JG; Guimaraes IM; Cregan SP; Ferguson SS
Expert Opin Ther Targets; 2014 Nov; 18(11):1293-304. PubMed ID: 25118797
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
[TBL] [Abstract][Full Text] [Related]
14. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.
Liu SY; Yu XL; Zhu J; Liu XM; Zhang Y; Dong QX; Ma S; Liu RT
Brain Res; 2018 Oct; 1697():21-33. PubMed ID: 29902468
[TBL] [Abstract][Full Text] [Related]
16. Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model.
Hamilton A; Vasefi M; Vander Tuin C; McQuaid RJ; Anisman H; Ferguson SS
Cell Rep; 2016 May; 15(9):1859-65. PubMed ID: 27210751
[TBL] [Abstract][Full Text] [Related]
17. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease.
Farrar AM; Murphy CA; Paterson NE; Oakeshott S; He D; Alosio W; McConnell K; Menalled LB; Ramboz S; Park LC; Howland D; Brunner D
J Huntingtons Dis; 2014; 3(2):145-58. PubMed ID: 25062858
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
[TBL] [Abstract][Full Text] [Related]
19. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.
Southwell AL; Smith-Dijak A; Kay C; Sepers M; Villanueva EB; Parsons MP; Xie Y; Anderson L; Felczak B; Waltl S; Ko S; Cheung D; Dal Cengio L; Slama R; Petoukhov E; Raymond LA; Hayden MR
Hum Mol Genet; 2016 Sep; 25(17):3654-3675. PubMed ID: 27378694
[TBL] [Abstract][Full Text] [Related]
20. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT.
Fang F; Peng T; Yang S; Wang W; Zhang Y; Li H
Int J Dev Neurosci; 2016 Aug; 52():66-74. PubMed ID: 27196502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
